Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v10-FR Version v2-FR
Language French French
Date Updated 2019-02-04 2018-10-09
Drug Identification Number 02357461 02357461
Brand name SANDOZ REPAGLINIDE SANDOZ REPAGLINIDE
Common or Proper name REPAGLINIDE REPAGLINIDE
Company Name SANDOZ CANADA INCORPORATED SANDOZ CANADA INCORPORATED
Ingredients REPAGLINIDE REPAGLINIDE
Strength(s) 1MG 1MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL
Packaging size 100 tab 100 tab
ATC code A10BX A10BX
ATC description BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Reason for shortage Requirements related to complying with good manufacturing practices. Requirements related to complying with good manufacturing practices.
Anticipated start date
Actual start date 2018-08-30 2018-08-30
Estimated end date 2019-02-04 2018-11-09
Actual end date 2019-01-31
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments
Health Canada comments